Streetbeat News

Stock Prices

VTYX

Ventyx Biosciences has initiated a Phase 2a trial for its drug VTX3232, targeting early Parkinson's Disease, with the first patient dosed. This marks a significant step in the company's drug development pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 12:03 pm

LE

Lands' End (NASDAQ:LE) has been analyzed by 7 analysts, all of whom are bullish. The average 12-month price target is $18.71, up 2.3% from the previous target. Despite positive analyst sentiment, Lands' End faces financial challenges, including declining revenue and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 12:01 pm

BCYC

Bicycle Therapeutics (NASDAQ:BCYC) has received mixed analyst ratings over the past three months, with a current average price target of $40.8, down from $43.50. Analysts have varied opinions, with some maintaining 'Buy' or 'Outperform' ratings, while one analyst lowered their rating to 'Neutral'. The company faces challenges with a 17.86% revenue decline but maintains strong net margins and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 12:01 pm

AFRM

Affirm Holdings (NASDAQ:AFRM) has received mixed analyst ratings over the past three months, with a recent average price target increase to $46.22. Analysts have raised their ratings and price targets, reflecting a positive outlook despite the company's financial challenges, such as low net margin and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 12:00 pm

DTE

DTE Energy (NYSE:DTE) has been the subject of analysis by 9 financial analysts over the past three months, with opinions ranging from bullish to bearish. The average 12-month price target has increased to $128.33, with a high of $137.00 and a low of $111.00. Analysts have recently raised their ratings and price targets, indicating positive sentiment. DTE Energy has shown strong financial performance with a 7.12% revenue growth rate, a net margin of 11.2%, and a return on equity of 2.89%. However, its debt-to-equity ratio is higher than the industry average, indicating higher financial risk.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 12:00 pm

MGX

Analysts have mixed views on Metagenomi (NASDAQ:MGX), with recent ratings showing a shift towards bullish sentiment. The average 12-month price target has decreased by 12.37% to $11.83. Metagenomi's financials show strong revenue growth but below-average industry performance.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 12:00 pm

CNM

Analysts have recently adjusted their ratings and price targets for Core & Main (NYSE:CNM), reflecting a more cautious outlook. The average 12-month price target has decreased by 13.56% to $48.62. Despite positive financial metrics like revenue growth and strong profitability, analysts have lowered their expectations due to market conditions.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 12:00 pm

CDAQU

The trading halt status was updated at 8:00:00 AM ET, indicating a resumption of quotations. This update is crucial for investors tracking the affected securities.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 12:00 pm

MBLY

Mobileye shares are experiencing a decline after reports emerged that Intel is considering selling a portion of its stake in the company.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:59 am

CDAQ

The trading halt status was updated at 7:55 AM ET, indicating a resumption of quotations. This update is crucial for investors tracking the affected securities.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:55 am